A soothing composition for relieving body itching and its application

Abstract

This invention discloses a soothing composition for relieving body itching and its application, relating to the field of cosmetic technology. The invention discloses a soothing and antipruritic composition comprising the following components in parts by weight: 0.1-0.5 parts of date palm seed, 1-5 parts of St. John's wort flower extract, 1-10 parts of Brazilian nectarine fruit oil, and 0.01-0.2 parts of L-homoserine. This invention, through the synergistic effect of date palm seed, St. John's wort flower extract, Brazilian nectarine fruit oil, and L-homoserine, on the one hand, helps to calm and soothe sensitive skin when there are temperature changes or improper care, and enhances the skin's resistance to external environmental influences; on the other hand, it can synergistically moisturize and soothe, reduce skin sensitivity, and prevent skin itching and dryness.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, and in particular to a soothing composition for relieving body itching and its application. Background Technology

[0002] Itching is a complex sensation involving the activation of specific physiological and cellular receptors. Sensory nerves extend into the epidermis, and external stimuli easily reach these nerves, releasing the pruritus factor Substance P (SP). SP binds to NK-1 receptors on mast cells, releasing substances such as histamine. Histamine induces itching by stimulating its homologous receptor (H1 receptor) and subsequently activating TRPV1 ion channels in sensory neurons. Itching is common in people with sensitive skin, especially dry and sensitive skin. Dry skin is caused by impaired skin barrier function due to environmental factors such as exposure to sunlight, temperature, and humidity. Generally, dry skin can induce chronic itching, a common clinical symptom of skin diseases. Over-cleansing can damage the skin barrier, and some surfactants can remain in the stratum corneum, causing irreversible damage to the keratinocyte membrane structure, leading to irritation and problems such as itching, rashes, and dermatitis.

[0003] Currently available products for relieving itching include corticosteroids, calamine lotion, and calcineurin inhibitors. However, these pose significant risks to people with sensitive skin, potentially leading to thinning and atrophy of the skin. Some products are also difficult to remove, leaving residues that can irritate the skin and negatively impact skin health. Summary of the Invention

[0004] Based on this, the purpose of the present invention is to overcome the shortcomings of the prior art and provide a soothing and antipruritic composition with soothing, moisturizing, antipruritic and barrier repair effects, as well as its preparation method and application.

[0005] To achieve the above objectives, in a first aspect of the present invention, the present invention provides a soothing and antipruritic composition comprising the following components in parts by weight: 0.1-0.5 parts of date seed, 1-5 parts of St. John's wort flower extract, 1-10 parts of Brazilian nectarine fruit oil, and 0.01-0.2 parts of L-homoserine.

[0006] This invention utilizes the synergistic effects of date seed, St. John's wort flower extract, Brazilian nectarine fruit oil, and L-homoserine in specific weight proportions to prepare a soothing and antipruritic composition with calming, moisturizing, antipruritic, and barrier-repairing properties, suitable for sensitive skin.

[0007] Date palm seeds (Phoenix dactylifera seeds), also known as date pits, are the seeds from the fruit of the date palm tree (also called the date palm). Date palm seeds contain abundant flavonoids, such as quercetin and rutin, as well as polyphenols, vitamin E, and phytosterols. These components have strong antioxidant properties, combating free radicals, reducing cell damage, and possessing anti-aging, anti-inflammatory, and anti-allergic effects. St. John's wort (Hypericum perforatum L.), belonging to the Clusiaceae family, has been shown by modern chemical analysis to contain 6 anthraquinone compounds; 7 flavonoid compounds; 35 terpenoid compounds; and small amounts of cinnamic acid derivatives and vanillic acid. Among these, the anthraquinone compound hypericin has significant pharmacological effects in antiviral, antidepressant, and antitumor activity. When used together, date seed and St. John's wort flower extracts can enhance each other's effects, producing a synergistic anti-inflammatory and antioxidant effect. They can also help soothe and calm sensitive skin when there are temperature changes or improper care, and enhance the skin's resistance to external environmental influences.

[0008] Brazilian nectarine oil is a plant oil extracted from the fruit of the Brazilian nectarine tree (Caryocar brasiliense). It has a very rich fatty acid composition, especially high in saturated fatty acids such as oleic acid and palmitic acid. Oleic acid accounts for approximately 40%-60%, which helps to deeply moisturize and repair the skin; it also contains polyunsaturated fatty acids, such as linoleic acid, which have excellent moisturizing effects, strengthen the skin barrier, and reduce moisture loss. L-homoserine is a non-essential amino acid containing one chiral carbon. It is not only a precursor compound for the synthesis of L-threonine and L-methionine, but also for the synthesis of valuable compounds such as O-acetylhomoserine, O-succinyl-L-homoserine, 1,3-propanediol, and isobutanol. Its amino and carboxyl group structures give it hydrophilicity, allowing it to bind with water molecules and thus possess excellent moisturizing properties. In the composition provided by this invention, L-homoserine provides hydration, while Brazilian nectarine oil provides moisturizing and deep repair. The combination helps the skin maintain an ideal water-oil balance, locking in moisture and preventing water loss, ensuring long-lasting hydration and comfort. This combination is particularly suitable for sensitive and inflamed skin. Therefore, Brazilian nectarine oil and L-homoserine synergistically moisturize and soothe, reduce skin sensitivity, promote smooth skin, and prevent itching and dryness.

[0009] This invention utilizes the synergistic effects of date seed extract, St. John's wort flower extract, Brazilian nectarine fruit oil, and L-homoserine to help soothe and calm sensitive skin in response to temperature changes and improper care, and enhance the skin's resistance to external environmental influences. Furthermore, it provides synergistic moisturizing and soothing effects, reduces skin sensitivity, and prevents itching and dryness.

[0010] Preferably, the soothing and antipruritic composition comprises the following components in parts by weight: 0.3-0.4 parts of date seed, 2-3 parts of St. John's wort flower extract, 5-8 parts of Brazilian peach fruit oil, and 0.05-0.1 parts of L-homoserine.

[0011] Preferably, the total mass percentage of Brazilian nectarine fruit oil and L-homoserine in the soothing and antipruritic composition is 65-75%.

[0012] The inventors discovered in their actual research that the weight proportions of the components in the soothing and antipruritic composition affect the performance of the product. When the weight proportions of the components are further selected within the above-mentioned range, the resulting product has superior soothing, moisturizing, antipruritic, and barrier repair effects.

[0013] Preferably, the hypericin content in the St. John's wort flower extract is 0.1-0.3% by mass.

[0014] Preferably, the hypericin content in the St. John's wort flower extract is 0.14-0.2% by mass.

[0015] The inventors discovered in their actual research that the mass percentage of hypericin in the St. John's wort flower extract has a significant impact on the antipruritic effect of the final soothing and antipruritic composition. The antipruritic effect is better when the mass percentage of hypericin in the St. John's wort flower extract is 0.14-0.2%.

[0016] In a second aspect of the present invention, the present invention provides a method for preparing St. John's wort flower extract as follows: St. John's wort flowers are pulverized and sieved to obtain St. John's wort flower powder, which is then mixed with an ethanol solution and protected from light. The mixture is then rotated, centrifuged, and the supernatant is collected. The supernatant is then concentrated and dried to obtain the St. John's wort flower extract.

[0017] Preferably, the volume fraction of the ethanol is 50-95%, and the weight ratio of the ethanol solution to the St. John's wort flower powder is 8-12:1.

[0018] Preferably, the rotational oscillation speed is 100-150 r / min, and the rotational oscillation time is 48-72 h; and / or, the centrifugation speed is 4000-6000 r / min, the centrifugation temperature is 2-6℃, and the centrifugation time is 5-15 min.

[0019] Preferably, the concentration temperature is 45-55°C.

[0020] More preferably, the volume fraction of the ethanol is 50-65%.

[0021] In a third aspect, the present invention provides the use of the described soothing and antipruritic composition in the preparation of skin products.

[0022] In a fourth aspect, the present invention provides a skin product comprising the aforementioned soothing and antipruritic composition.

[0023] Preferably, the skin care products include any one of toner, lotion, cream, mask, serum, and spray.

[0024] Preferably, the skin product comprises the following components in weight percentage: 1-5% soothing and antipruritic composition, 4-40% cosmetic base, and the balance being water.

[0025] Preferably, the cosmetic base includes at least one of thickener, moisturizer, emulsifier, skin conditioner, antioxidant, emollient, preservative, fragrance, and pH adjuster.

[0026] Preferably, the present invention provides a body lotion comprising the following components in weight percentage: 1-5% soothing and antipruritic composition, 1-10% moisturizer, 0.1-0.5% thickener, 0.5-5% emulsifier, 0.05-1% skin conditioning agent, 0.5-1% antioxidant, 2-12% emollient, and the balance being deionized water.

[0027] For example, the moisturizer includes at least one of glycerin, butylene glycol, low molecular weight sodium hyaluronate, and 1,2-hexanediol; the thickener includes at least one of xanthan gum, carbomer 980, high molecular weight cellulose, and polyacrylate crosspolymer-6; the emulsifier includes at least one of C12-20 alkyl glucoside, C14-22 alcohol, polydimethylsiloxane, hydrogenated palm kernel oil, cetearyl alcohol, polyglycerol-6 distearate, arachidonic acid, behenol, and arachidonic acid glucoside; the skin conditioning agent includes at least one of trehalose and allantoin; the antioxidant includes at least one of p-hydroxyacetophenone and tocopheryl acetate; and the emollient includes at least one of polydimethylsiloxane, butyrospermum parkii fruit butter, caprylic / capric triglyceride, petrolatum, and stearyl alcohol.

[0028] Compared with the prior art, the beneficial effects of the present invention are as follows: The present invention, through the synergistic effect of date seed, St. John's wort flower extract, Brazilian nectarine fruit oil, and L-homoserine, can, on the one hand, help soothe and calm sensitive skin when there are temperature changes or improper care, and enhance the skin's resistance to external environmental influences; on the other hand, it can synergistically moisturize and soothe, reduce skin sensitivity, and prevent skin itching and dryness. Attached Figure Description

[0029] Figure 1 The following are the results of the keratinocyte viability test in performance test 1: (a) is the result of the cell viability test in the blank control group, (b) is the result of the cell viability test in Example 1, and (c) is the result of the cell viability test in Comparative Example 1.

[0030] Figure 2 The images show the immunofluorescence detection results of TRPV1 in performance test 2, where (d) is the immunofluorescence detection result of TRPV1 in the blank control group, (e) is the immunofluorescence detection result of TRPV1 in the negative control group, (f) is the immunofluorescence detection result of TRPV1 in Example 1, and (g) is the immunofluorescence detection result of TRPV1 in Comparative Example 1.

[0031] Figure 3 The graphs show the results of the scaling test in performance test 5, where (h) is the scaling test result of the blank application example, (i) is the scaling test result of application example 1, and (j) is the scaling test result of the comparison application example 1. Detailed Implementation

[0032] To better illustrate the purpose, technical solution, and advantages of this invention, the invention will be further described below in conjunction with the accompanying drawings and specific embodiments. The purpose is to provide a detailed understanding of the invention, not to limit it. All other embodiments obtained by those skilled in the art without inventive effort are within the scope of protection of this invention. Unless otherwise specified, the experimental reagents and instruments designed in the embodiments and comparative examples of this invention are commonly used reagents and instruments, all of which are commercially available. Unless otherwise specified, the experimental methods used in the embodiments and comparative examples are conventional methods; and unless otherwise specified, the raw materials used in parallel experiments are from the same batch.

[0033] The raw materials used in the embodiments and comparative examples of the present invention are described below, but are not limited to the following raw materials:

[0034] Date seed: Product name is Purchased from Lucas Meyer Cosmetics;

[0035] Brazilian nectarine fruit oil: Product name is Purchased from Guangzhou Baiyun District Mingliuji Electronic Trading Company;

[0036] L-homoserine: Product Name Evermild TM L-HS, purchased from Shengde Biotech Technology Co., Ltd.;

[0037] Brazil nut seed extract: Product name Ethience Protect, purchased from Lucas Meyer Cosmetics;

[0038] Sea buckthorn fruit oil: Model 7012, purchased from Heze Zhonghe Jianyuan Biotechnology Co., Ltd.;

[0039] L-Serine: Model CDAA-270014, purchased from Shanghai Anpu Experimental Technology Co., Ltd.;

[0040] St. John's wort flower extract-1: self-made, the preparation method is as follows: (1) St. John's wort flowers are crushed and passed through a 0.177mm sieve to obtain St. John's wort flower powder, mixed with a 50% volume fraction ethanol solution and sealed, and kept at room temperature in the dark (dark conditions); the weight ratio of the ethanol solution to the St. John's wort flower powder is 8:1; (2) The above mixture is rotated and centrifuged, the supernatant is collected, and concentrated by rotary evaporation at 45℃. After concentration, it is placed in an ultra-low temperature freeze dryer to dry and freeze to obtain the St. John's wort flower extract; the rotation speed is 120r / min, the rotation time is 72h; the centrifugation speed is 5000r / min, the centrifugation temperature is 4℃, and the centrifugation time is 10min.

[0041] St. John's wort flower extract-2: prepared in-house, the preparation method is the same as that of St. John's wort flower extract-1, except that the volume fraction and amount of ethanol solution are different; the St. John's wort flower powder is mixed with a 60% ethanol solution and sealed, then stored in the dark at room temperature. The weight ratio of the ethanol solution to the St. John's wort flower powder is 10:1.

[0042] St. John's wort flower extract-3: prepared in-house, the preparation method is the same as that of St. John's wort flower extract-1, except that the volume fraction and amount of ethanol solution are different; the St. John's wort flower powder is mixed with a 70% ethanol solution and sealed, then stored in the dark at room temperature. The weight ratio of the ethanol solution to the St. John's wort flower powder is 10:1.

[0043] St. John's wort flower extract-4: prepared in-house, the preparation method is the same as that of St. John's wort flower extract-1, except that the volume fraction and amount of ethanol solution are different; the St. John's wort flower powder is mixed with a 95% ethanol solution and sealed, then stored in the dark at room temperature. The weight ratio of the ethanol solution to the St. John's wort flower powder is 12:1.

[0044] The hypericin content in extracts 1-4 of St. John's wort flowers was determined by HPLC, and the hypericin contents of extracts 1-4 were 0.14%, 0.18%, 0.25%, and 0.11%, respectively.

[0045] Examples and Comparative Examples

[0046] The present invention provides a soothing and antipruritic composition in embodiments and comparative examples. The components and weight parts of the soothing and antipruritic composition are shown in Tables 1 and 2. The preparation method of the soothing and antipruritic composition includes the following steps: ultrasonically mixing date seed, St. John's wort flower extract, Brazilian peach fruit oil, and L-homoserine until uniform to obtain the soothing and antipruritic composition; in the comparative examples, if the relevant components are not present, they are not added; if the substitute components are present, they are added together.

[0047] Table 1

[0048]

[0049]

[0050] Table 2

[0051]

[0052] Application examples

[0053] This invention provides a body lotion, the components (mass percentage) of which are shown in Table 3. The soothing and antipruritic compositions used in Application Examples 1-8 are those prepared in Examples 1-8, respectively. The soothing and antipruritic compositions used in Comparative Application Examples 1-6 are those prepared in Comparative Examples 1-6, respectively. The blank application examples do not contain any soothing and antipruritic composition. For example, the soothing and antipruritic composition used in Application Example 1 is the one from Example 1; the soothing and antipruritic composition used in Application Example 5 is the one from Example 5; the soothing and antipruritic composition used in Application Example 8 is the one from Example 8, and so on. The soothing and antipruritic composition used in Application Example 9 is the one prepared in Example 1.

[0054] Table 3

[0055]

[0056] The method for preparing the body lotion provided in Application Example 1 is as follows:

[0057] (1) Mix component A with water and stir. Heat to 80°C and homogenize at 1200 rpm for 5 minutes. After homogenization, keep warm for later use to obtain pre-prepared component A.

[0058] (2) Mix component B, heat to 80°C, homogenize at 1200 rpm for 5 min, keep warm after homogenization, and obtain pre-prepared component B.

[0059] (3) Mix component C and heat to 60°C to melt it to obtain pre-prepared component C;

[0060] (4) Heat the pre-prepared component A to 80°C, add the pre-prepared component B at 300 rpm, stir and mix, then cool down to 60°C, add the pre-prepared component C at 300 rpm and stir and mix, then cool down to below 45°C, add the soothing and antipruritic composition and continue stirring for 5 minutes, and discharge the emulsion.

[0061] The preparation methods for the other application examples, comparative application examples, and blank application examples are the same as those for application example 1; if the relevant components are not available, they can be omitted.

[0062] Performance Testing - 1 Cell Viability Test

[0063] The effects of the soothing and antipruritic compositions prepared in the examples and comparative examples on cell viability were investigated.

[0064] Experimental materials: Phosphate-buffered saline (PBS), Shanghai Solarbio; Shanghai Solarbio; Thiazol blue (MTT), Yuanye Biotechnology; Dimethyl sulfoxide (DMSO), Tianjin Damao; High glucose medium 1×DMEM, Gibco; Fetal bovine serum (FBS), Gibco; Keratinocytes purchased from Guangzhou Customs Technology Center.

[0065] Experimental Procedure: Cell suspension was seeded into 96-well cell culture plates and incubated for 24 hours. The original culture medium was discarded. 100 μL of the test sample (the soothing and antipruritic composition dissolved in DMSO to a final concentration of 0.06%) was added to each well in the sample group and incubated for 24 hours. Culture medium was added to the blank control group. The culture plate was removed, and 20 μL of MTT solution was added to each well. Incubation was performed for 3-4 hours. The liquid in the wells was removed, and 100 μL of DMSO was added to each well. After shaking for 10-15 minutes, the absorbance (OD) was measured at 570 nm using a microplate reader, and cell viability was calculated. Experimental data are expressed as mean ± standard deviation (Mean ± SD). A t-test was used for data comparison and analysis. Compared with the blank control, * indicates statistical significance; *P < 0.05, significant; **P < 0.01, highly significant; ***P < 0.001, highly significant.

[0066] Cell viability (%) = (OD value of sample wells - OD value of zeroing wells) / (OD value of blank control wells - OD value of zeroing wells) × 100%.

[0067] The test results are shown in Table 4.

[0068] Table 4

[0069] sample Cell viability (%) Blank control group 100.00 Example 1 115.53** Example 2 114.87** Example 3 114.90** Example 4 114.69** Example 5 115.21** Example 6 104.27* Example 7 104.11* Example 8 110.24* Comparative Example 1 101.19 Comparative Example 2 100.82 Comparative Example 3 100.98 Comparative Example 4 99.98 Comparative Example 5 100.11 Comparative Example 6 100.07

[0070] Figure 1 The figures show the results of the keratinocyte viability test, where (a) is the result of the cell viability test in the blank control group, (b) is the result of the cell viability test in Example 1, and (c) is the result of the cell viability test in Comparative Example 1; Example 1 of the present invention can effectively enhance cell viability.

[0071] As shown in the table above, the soothing and antipruritic composition prepared in the embodiments of the present invention has a good effect on improving cell vitality. A comparison of Examples 1-4 shows that the mass percentage of hypericin in the extract of St. John's wort flower has little difference in its effect on cell vitality.

[0072] A comparison of Examples 1 and 5-8 shows that the soothing and antipruritic composition exhibits better cell-enhancing effects when the following weight proportions are selected: 0.3-0.4 parts of date palm seed, 2-3 parts of St. John's wort flower extract, 5-8 parts of Brazilian nectarine fruit oil, and 0.05-0.1 parts of L-homoserine. Furthermore, the soothing and antipruritic composition demonstrates even better cell-enhancing effects when the total mass percentage of Brazilian nectarine fruit oil and L-homoserine is 65-75%.

[0073] Comparative Examples 1-6 lacked some components or were not specific to this invention, including date seed extract, St. John's wort flower extract, Brazilian peach fruit oil, and L-homoserine synergistic effect. The results showed that they had little impact on cell viability.

[0074] Performance Testing - 2TRPV1 Suppression Test

[0075] This invention verifies the inhibitory effect of the soothing and antipruritic compositions prepared in the examples and comparative examples on TRPV1 expression. TRPV1 is a transiently opening, non-selective cation channel that can be activated by heat, weak acids, capsaicin, and some endogenous ligands. In the skin, TRPV1 channels are first identified at nociceptive sensory nerve endings and participate in many sensory afferent functions (such as the sensation of pain, itching, temperature, and chemical stimuli) and efferent functions (local (neurogenic inflammation via the release of various neuropeptides) and systemic (release of analgesic neuropeptides). TRPV1 and histamine receptors are co-expressed in sensory afferent fibers. Studies have shown that inhibitors of TRPV1 can reduce histamine-induced calcium ion influx on DRG neurons, thereby alleviating itching. Specifically, this includes the following:

[0076] (1) Grouping information: The samples were divided into sample group (the soothing and antipruritic compositions in the examples and comparative examples), positive control group (PC, novanillin), negative control group (NC), and blank control group (BC);

[0077] (2) Experimental steps: Epidermal skin model Transfer the samples to well plates, pre-add EpiGrowth medium, label the well plates with test group numbers, and make three replicates for each group. Groups BC received no treatment. Groups NC, PC, and the sample group received 15 μM EpiGrowth medium containing capsaicin (CAP). Groups PC and the sample group received the corresponding concentration of working sample solution (the concentration of the PC group was adjusted to 15.6 μg / mL with culture medium, and the volume concentration of the working sample was 0.015% of the culture medium). Distribute the samples evenly on the model surface and incubate in a CO2 incubator (37℃, 5% CO2) for 24 h. After incubation, clean the model surface with sterile PBS solution to remove any remaining test material, and wipe the inside and outside of the model with sterile cotton swabs to remove any remaining liquid.

[0078] (3) TRPV1 detection: The fixation was performed with 4% paraformaldehyde for 30 min, and the capsaicin receptor TRPV1 was detected by immunofluorescence. The images were photographed and observed under a microscope, and the optical density values ​​(IOD) were collected, analyzed and recorded.

[0079] (4) Statistical analysis of results: Results are expressed as Mean±SD; t-test statistical analysis was used for comparison between groups; *P<0.05 was considered to be statistically significant, and **P<0.01 was considered to be highly statistically significant.

[0080] The inhibition rate is calculated as follows: Inhibition rate (%) = (Relative IOD average of negative control group - Relative IOD average of sample group) / Relative IOD average of negative control group × 100%;

[0081] The relative IOD refers to the cumulative optical density in each reaction well during each measurement, which is a unitless relative value; the average relative IOD refers to the average of the relative IOD values ​​obtained from each measurement of the three parallel reaction wells.

[0082] The test results are shown in Table 5.

[0083] Table 5

[0084]

[0085]

[0086] Figure 2 The images show the immunofluorescence detection results of TRPV1, where (d) is the immunofluorescence detection result of TRPV1 in the blank control group, (e) is the immunofluorescence detection result of TRPV1 in the negative control group, (f) is the immunofluorescence detection result of TRPV1 in Example 1, and (g) is the immunofluorescence detection result of TRPV1 in Comparative Example 1. The soothing and antipruritic composition prepared in Example 1 of this invention has a significantly better inhibition rate on TRPV1 expression.

[0087] As shown in the table above, the soothing and antipruritic composition prepared in the embodiments of the present invention has an inhibition rate of over 40% on TRPV1 expression. A comparison of Examples 1-4 shows that when the mass percentage of hypericin in the extract of St. John's wort is 0.14-0.2%, the inhibition rate on TRPV1 expression is higher, and the antipruritic effect is better.

[0088] A comparison of Examples 1 and 5-8 shows that, in the soothing and antipruritic composition, the following weight proportions—0.3-0.4 parts of date palm seed, 2-3 parts of St. John's wort flower extract, 5-8 parts of Brazilian nectarine fruit oil, and 0.05-0.1 parts of L-homoserine—resulted in a higher inhibition rate of TRPV1 expression and a better antipruritic effect. Furthermore, when the total mass percentage of Brazilian nectarine fruit oil and L-homoserine in the soothing and antipruritic composition was 65-75%, the inhibition rate of TRPV1 expression was even higher, and the antipruritic effect was even better.

[0089] Comparative Examples 1-6 lacked some components or were not specific to this invention, including date seed extract, St. John's wort flower extract, Brazilian peach fruit oil, and L-homoserine synergistic effect. The results showed that the antipruritic effect was poor.

[0090] Performance Test - 3 Inflammatory Factor Inhibition Test

[0091] Experimental materials: The cell line used was mouse macrophage RAW264.7, purchased from the Cell Resource Center of the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences; fetal bovine serum (FBS, Gibco); DMEM high glucose medium (DMEM, Gibco); dimethyl sulfoxide (DMSO, Sigma); phosphate-buffered saline (PBS, Gibco); thiazolyl blue (MTT, Sigma); and mouse interleukin-1β ELISA kit (Boster).

[0092] Experimental procedure: Seed cells into 24-well plates and incubate at 37°C in a 5% CO2 incubator for 24 hours;

[0093] According to the experimental grouping and concentration settings in Table 6, after the cells in the 24-well plates had grown for 24 hours, samples were added to the treatment groups, with 3 replicates for each treatment group. Cell culture medium was added to both the blank control and negative control groups, while cell culture medium containing the corresponding concentration of the sample was added to the sample groups. The cells were then incubated at 37°C in a 5% CO2 incubator for another 24 hours.

[0094] The culture medium was aspirated from the plate, and each well was washed once with PBS. Cell culture medium was added to the blank control group, while cell culture medium containing lipopolysaccharide (LPS) was added to the negative control group, sample group, and positive control group. The cells were incubated at 37°C in a 5% CO2 incubator for 24 hours, and the supernatant was collected. The cell supernatant from each well was used to detect the content of cellular inflammatory factors according to the ELISA kit instructions. All data obtained in the experiment were processed and plotted using Excel software. Statistical analysis was performed using SPSS 17.0. One-way ANOVA was used for comparisons between groups. A p-value < 0.05 was considered statistically significant. The results are shown in Table 7. The inhibition rate was calculated as follows: Inhibition rate (%) = (average concentration of negative control group - average concentration of sample group) / average concentration of negative control group × 100%.

[0095] Table 6

[0096]

[0097] Table 7

[0098]

[0099]

[0100] As shown in the table above, the soothing and antipruritic compositions prepared in the embodiments of the present invention have excellent anti-inflammatory effects. A comparison of Examples 1-4 shows that the mass percentage of hypericin in the extract of St. John's wort flower has little effect on the anti-inflammatory effect.

[0101] A comparison of Examples 1 and 5-8 shows that the anti-inflammatory effect is better when the following weight parts are selected in the soothing and antipruritic composition: 0.3-0.4 parts of date palm seed, 2-3 parts of St. John's wort flower extract, 5-8 parts of Brazilian nectarine fruit oil, and 0.05-0.1 parts of L-homoserine. The anti-inflammatory effect is even better when the total mass percentage of Brazilian nectarine fruit oil and L-homoserine in the soothing and antipruritic composition is 65-75%.

[0102] Comparative Examples 1-6 lacked some components or were not specific to this invention, including date seed extract, St. John's wort flower extract, Brazilian peach fruit oil, and L-homoserine synergistic effect. The results showed that the anti-inflammatory effect was poor.

[0103] Performance Testing - 4. Mildness Testing

[0104] This invention verifies the mildness of the applied emulsion on human skin. Following the "Cosmetic Safety Technical Specifications" (2015) for human skin patch testing, 33 volunteers aged 18-60 years were recruited. The test environment was a temperature of (21±1)℃ and a humidity of (50±10)%. Volunteers washed their forearms with water. After 5-10 minutes, once the moisture had evaporated, the testers applied 0.020-0.025 mL of each sample emulsion to each chamber of a 10-well patch applicator. The inner sides of both forearms of the volunteers were selected, avoiding the skin around the joints of the front and back of the hands. Each arm was covered with a patch applicator and marked accordingly. The patch application lasted for 24 hours. After removing the patch applicator and wiping away any remaining sample, skin reactions were observed at 0.5h, 24h, and 48h. The results were recorded according to the skin reaction grading standards in the "Cosmetic Safety Technical Specifications" (2015). As shown in Table 8, skin reactions were divided into four rating levels; the higher the score, the more severe the skin irritation.

[0105] Table 8

[0106]

[0107] After testing, the body lotions prepared in the application examples, comparative application examples, and blank application examples of this invention all showed negative reactions after human patch testing, indicating that they are safe and non-irritating to human skin.

[0108] Performance Test - 5 Human Skin Repair and Moisturizing Effects

[0109] This invention verifies the efficacy of application examples, comparative application examples, and blank application examples on the human body, specifically including the following methods: According to the "Cosmetic Safety Technical Specifications" (2015), subjects aged 18-60 years who frequently experience body itching were selected for the experiment. Under normal conditions, the subjects were randomly assigned to 16 groups of 5 each. The product was used continuously for 28 days in a winter environment during December. Skin indicators were measured using instruments and clinically evaluated on days 0, 7, 14, and 28 of the test.

[0110] The specific measurement steps are as follows: After showering every evening, the subject applied 1.5 mL of body lotion to the forearm flexion area and massaged it in until absorbed. On the day of the visit, the subject cleansed with water without applying any product and sat quietly for 20 minutes in an air-conditioned room with a temperature of 21±1℃ and humidity of 50±10%. The MMV values ​​before and after sample use were measured using a Corneometer (CM 825, Courage and Khazaka); the TEWL values ​​before and after sample use were measured using a TewaMeter (TMHex, Courage+Khazaka); and the scaling index was tested using VC 20Plus.

[0111] Record the data and calculate the indicator improvement rate on day 28. The indicator improvement rate = |value before use - value after use| / value before use × 100%. The test results are shown in Table 9.

[0112] Table 9

[0113]

[0114] Figure 3 The figures show the results of the scaling test, where (h) is the scaling test result of the blank application example, (i) is the scaling test result of application example 1, and (j) is the scaling test result of the comparative application example 1. The body lotion in application example 1 of this invention significantly improved the scaling condition after use.

[0115] As shown in the table above, the body lotion prepared using the examples of this invention has excellent repairing and moisturizing effects, and significantly improves scaling after use. A comparison of Examples 1-4 shows that the mass percentage of hypericin in the St. John's wort flower extract has little difference in its effect on repairing and moisturizing effects, or on the condition of scaling after use.

[0116] A comparison of Examples 1 and 5-8 shows that the soothing and antipruritic composition exhibits better repair and moisturizing effects and significantly improves scaling after use when the following weight proportions are selected: 0.3-0.4 parts of date palm seed, 2-3 parts of St. John's wort flower extract, 5-8 parts of Brazilian nectarine fruit oil, and 0.05-0.1 parts of L-homoserine. Furthermore, when the total mass percentage of Brazilian nectarine fruit oil and L-homoserine in the soothing and antipruritic composition is 65-75%, the repair and moisturizing effects are even better, and the scaling condition is significantly improved after use.

[0117] Comparative Examples 1-6 lacked some components or were not specific to this invention, such as date seed extract, St. John's wort flower extract, Brazilian peach fruit oil, and L-homoserine synergistic effect. The results showed that the repair and moisturizing effects were poor, and the improvement of scaling was not obvious after use.

[0118] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. A soothing and antipruritic composition, characterized in that, The product comprises the following components in parts by weight: 0.1-0.5 parts of date palm seeds, 1-5 parts of St. John's wort flower extract, 1-10 parts of Brazilian nectarine fruit oil, and 0.01-0.2 parts of L-homoserine; the mass percentage of hypericin in the St. John's wort flower extract is 0.14-0.2%; the preparation method of the St. John's wort flower extract is as follows: St. John's wort flowers are pulverized and sieved to obtain St. John's wort flower powder, which is mixed with an ethanol solution and then protected from light. The mixture is then rotated, centrifuged, and the supernatant is collected. The supernatant is concentrated and dried to obtain the St. John's wort flower extract; the volume fraction of the ethanol is 50-60%, and the weight ratio of the ethanol solution to the St. John's wort flower powder is 8-10:

1.

2. The soothing and antipruritic composition according to claim 1, characterized in that, It includes the following components in parts by weight: 0.3-0.4 parts of date seed, 2-3 parts of St. John's wort flower extract, 5-8 parts of Brazilian peach fruit oil, and 0.05-0.1 parts of L-homoserine.

3. The soothing and antipruritic composition according to claim 1, characterized in that, The total mass percentage of Brazilian nectarine fruit oil and L-homoserine in the soothing and antipruritic composition is 65-75%.

4. The soothing and antipruritic composition according to claim 1, characterized in that, The rotational oscillation speed is 100-150 r / min, and the rotational oscillation time is 48-72 h; and / or, the centrifugation speed is 4000-6000 r / min, the centrifugation temperature is 2-6℃, and the centrifugation time is 5-15 min.

5. The use of the soothing and antipruritic composition according to any one of claims 1-4 in the preparation of skin products.

6. A skin care product, characterized in that, The skin product includes the soothing and antipruritic composition as described in any one of claims 1-4.

Images